Ionis Pharmaceuticals (IONS) Accumulated Expenses (2009 - 2026)

Ionis Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $36.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 64.91% year-over-year to $36.0 million in Q1 2026; TTM through Mar 2026 was $36.0 million, a 64.91% decrease from a year earlier, with the FY2025 full-year figure at $106.1 million, down 2.17% from the prior year.
• Accumulated Expenses fell to $36.0 million in Q1 2026 per IONS's latest filing, from $106.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $147.9 million in Q4 2023 and bottomed at $18.2 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $99.3 million (2022), against an average of $79.0 million.
• Across the five-year window, Accumulated Expenses tumbled 81.7% in 2023 and jumped 483.96% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $140.1 million in 2022, then gained by 5.56% to $147.9 million in 2023, then declined by 26.68% to $108.4 million in 2024, then retreated by 2.17% to $106.1 million in 2025, then tumbled by 66.02% to $36.0 million in 2026.
• Per Business Quant, the three latest IONS Accumulated Expenses figures stand at $36.0 million (Q1 2026), $106.1 million (Q4 2025), and $99.3 million (Q3 2025).